valproic acid has been researched along with Atrophy in 37 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "A 5-year-old female developed alteration of consciousness during 3 days of long-term treatment with valproic acid for localization-related epilepsy." | 7.72 | Reversible altered consciousness with brain atrophy caused by valproic acid. ( Eguchi, M; Imataka, G; Nakagawa, E; Ota, T; Yamanouchi, H, 2003) |
| "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease." | 7.68 | Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. ( Colombo, JP; Straver, JS; van der Vijver, JC; van Woerkom, TC; Verbiest, HB, 1992) |
| "We evaluated the effect of the divalproex sodium formulation of valproic acid on brain volumes using MRI in people with mild to moderate Alzheimer disease (AD) and assessed for changes associated with behavioral and cognitive effects." | 5.15 | Chronic divalproex sodium use and brain atrophy in Alzheimer disease. ( Aisen, PS; Cummings, JL; Fleisher, AS; Jack, CR; Langbaum, JB; Mai, JT; Schneider, LS; Tariot, PN; Thomas, RG; Truran, D; Weiner, MW, 2011) |
| "Magnetic resonance (MR) multimodality evoked potentials (MEPs) and clinical findings were correlated in a 47-year-old epileptic man in whom parenteral valproic acid (VPA) therapy induced severe comatose hyperammonemic encephalopathy without biological signs of hepatotoxicity (or hepatocytic dysfunction)." | 3.73 | Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma. ( Duprez, T; Grandin, C; Guérit, JM; Hantson, P; Nassogne, MC, 2005) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "A 5-year-old female developed alteration of consciousness during 3 days of long-term treatment with valproic acid for localization-related epilepsy." | 3.72 | Reversible altered consciousness with brain atrophy caused by valproic acid. ( Eguchi, M; Imataka, G; Nakagawa, E; Ota, T; Yamanouchi, H, 2003) |
| "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease." | 3.68 | Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. ( Colombo, JP; Straver, JS; van der Vijver, JC; van Woerkom, TC; Verbiest, HB, 1992) |
| "Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity." | 2.76 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. ( Aisen, PS; Bartocci, B; Cummings, J; Fleisher, A; Ismail, MS; Jack, CR; Jakimovich, LJ; Loy, R; Porsteinsson, A; Raman, R; Schneider, LS; Tariot, PN; Thal, L; Thomas, RG; Weiner, M, 2011) |
| "Mood disorders have traditionally been conceptualized as neurochemical disorders, but there is now evidence from a variety of sources demonstrating regional reductions in central nervous system (CNS) volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas." | 2.42 | The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. ( Du, J; Gray, NA; Manji, HK; Moore, GJ; Zhou, R, 2003) |
| "Valproic acid-treated animals developed biochemical evidence of FS as judged by elevated serum gamma-glutamyl transferase (γ-GT), alkaline phosphatase (ALP), creatinine (Cr), and blood urea nitrogen (BUN) along with hypokalaemia, hypophosphataemia, and a decrease in serum uric acid." | 1.48 | Mechanism of valproic acid-induced Fanconi syndrome involves mitochondrial dysfunction and oxidative stress in rat kidney. ( Heidari, R; Jafari, F; Khodaei, F; Niknahad, H; Shirazi Yeganeh, B, 2018) |
| "Although most patients with infantile Alexander disease have epilepsy, infantile spasms are rare." | 1.39 | Alexander disease with mild dorsal brainstem atrophy and infantile spasms. ( Hara, T; Ishizaki, Y; Sanefuji, M; Sawaishi, Y; Torisu, H; Yamaguchi-Takada, Y; Yano, T; Yoshikawa, Y, 2013) |
| " In many situations, the final choice of an antiepileptic drug may need a change due to the agent's side-effect profile." | 1.37 | Cerebellar atrophy in a child with valproate toxicity. ( Bhatt, S; Ghosh, VB; Kapoor, S; Prakash, A, 2011) |
| "We describe a case of catatonia in a 51-year-old man in whom the catatonic symptoms could not be distinguished from symptoms of frontotemporal dementia (FTD) until they were resolved with electroconvulsive therapy (ECT)." | 1.35 | A case of catatonia resembling frontotemporal dementia and resolved with electroconvulsive therapy. ( Matsuoka, H; Suzuki, K; Takano, T, 2009) |
| "Levetiracetam (LEV) treatment was started in combination with VPA in a patient with typical clinical, histological, and biochemical features of MERRF due to a mutation on the tRNA of Phenilalanine gene." | 1.33 | Antimyoclonic effect of levetiracetam in MERRF syndrome. ( Filosto, M; Galli, R; Mancuso, M; Murri, L; Pizzanelli, C; Siciliano, G, 2006) |
| "EEG showed typical hypsarrhythmia in 8 cases, asymmetrical hypsarrhythmia in 1 case and modified hypsarrhythmia in another case." | 1.30 | [West's syndrome in patients with cerebral paralysis and periventricular leukomalacia: a good response to treatment]. ( Caraballo, R; Cersósimo, R; Fejerman, N; Intruvini, S; Pociecha, J, 1997) |
| " Reduction of VPA dosage and subsequent discontinuation 4 months later resulted in disappearance of clinical symptoms with a 20-point improvement at IQ testing and recovery of previous PM score." | 1.30 | Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. ( Belmonte, A; Canapicchi, R; Casalini, C; Guerrini, R; Perucca, E, 1998) |
| "Macro square wave jerks and pendular nystagmus were mildly suppressed after the intramuscular injection of 100 mg of phenobarbital, the oral intake of sodium valproate of 600 mg/day or baclofen of 60 mg/day." | 1.28 | [Multiple system atrophy with macro square wave jerks and pendular nystagmus]. ( Fukusako, T; Morimatsu, M; Nogaki, H; Yamamoto, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.41) | 18.7374 |
| 1990's | 10 (27.03) | 18.2507 |
| 2000's | 13 (35.14) | 29.6817 |
| 2010's | 12 (32.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lv, Y | 1 |
| Zhang, N | 1 |
| Liu, C | 1 |
| Shi, M | 1 |
| Sun, L | 1 |
| Zhang, Y | 1 |
| Xiang, Z | 1 |
| Jia, Y | 1 |
| He, X | 1 |
| Wang, L | 1 |
| Cui, W | 1 |
| Ennaim, N | 1 |
| Bourrous, M | 1 |
| Rada, N | 1 |
| Draiss, G | 1 |
| Bouskraoui, M | 1 |
| Ene-Stroescu, V | 1 |
| Nguyen, T | 1 |
| Waiblinger, BE | 1 |
| Bhat, RY | 1 |
| Kakkar, S | 1 |
| Prakashini, K | 1 |
| Lovett, M | 1 |
| Skidmore, DL | 1 |
| Mohamed, IS | 1 |
| Moyal, D | 1 |
| Sanyal, S | 1 |
| Khanna, A | 1 |
| Heidari, R | 1 |
| Jafari, F | 1 |
| Khodaei, F | 1 |
| Shirazi Yeganeh, B | 1 |
| Niknahad, H | 1 |
| Abreu, LN | 1 |
| Issler, C | 1 |
| Lafer, B | 1 |
| Ghosh, VB | 1 |
| Kapoor, S | 1 |
| Prakash, A | 1 |
| Bhatt, S | 1 |
| Tariot, PN | 2 |
| Schneider, LS | 2 |
| Cummings, J | 1 |
| Thomas, RG | 2 |
| Raman, R | 1 |
| Jakimovich, LJ | 1 |
| Loy, R | 1 |
| Bartocci, B | 1 |
| Fleisher, A | 1 |
| Ismail, MS | 1 |
| Porsteinsson, A | 1 |
| Weiner, M | 1 |
| Jack, CR | 2 |
| Thal, L | 1 |
| Aisen, PS | 2 |
| Fleisher, AS | 1 |
| Truran, D | 1 |
| Mai, JT | 1 |
| Langbaum, JB | 1 |
| Cummings, JL | 1 |
| Weiner, MW | 1 |
| Torisu, H | 1 |
| Yoshikawa, Y | 1 |
| Yamaguchi-Takada, Y | 1 |
| Yano, T | 1 |
| Sanefuji, M | 1 |
| Ishizaki, Y | 1 |
| Sawaishi, Y | 1 |
| Hara, T | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Gray, NA | 1 |
| Zhou, R | 1 |
| Du, J | 1 |
| Moore, GJ | 2 |
| Manji, HK | 2 |
| Yamanouchi, H | 1 |
| Ota, T | 1 |
| Imataka, G | 1 |
| Nakagawa, E | 1 |
| Eguchi, M | 1 |
| Hantson, P | 1 |
| Grandin, C | 1 |
| Duprez, T | 1 |
| Nassogne, MC | 1 |
| Guérit, JM | 1 |
| Kaur, S | 1 |
| Sassi, RB | 1 |
| Axelson, D | 1 |
| Nicoletti, M | 1 |
| Brambilla, P | 1 |
| Monkul, ES | 1 |
| Hatch, JP | 1 |
| Keshavan, MS | 1 |
| Ryan, N | 1 |
| Birmaher, B | 1 |
| Soares, JC | 1 |
| Mancuso, M | 1 |
| Galli, R | 1 |
| Pizzanelli, C | 1 |
| Filosto, M | 1 |
| Siciliano, G | 1 |
| Murri, L | 1 |
| Galimberti, CA | 1 |
| Diegoli, M | 1 |
| Sartori, I | 1 |
| Uggetti, C | 1 |
| Brega, A | 1 |
| Tartara, A | 1 |
| Arbustini, E | 1 |
| Ferrero, AJ | 1 |
| Cereseto, M | 1 |
| Sifonios, LL | 1 |
| Reinés, A | 1 |
| Peixoto, E | 1 |
| Rubio, MC | 1 |
| Wikinski, S | 1 |
| Suzuki, K | 1 |
| Takano, T | 1 |
| Matsuoka, H | 1 |
| Papazian, O | 1 |
| Cañizales, E | 1 |
| Alfonso, I | 1 |
| Archila, R | 1 |
| Duchowny, M | 1 |
| Aicardi, J | 1 |
| Baganz, MD | 1 |
| Dross, PE | 1 |
| Caraballo, R | 1 |
| Cersósimo, R | 1 |
| Intruvini, S | 1 |
| Pociecha, J | 1 |
| Fejerman, N | 1 |
| Guerrini, R | 1 |
| Belmonte, A | 1 |
| Canapicchi, R | 1 |
| Casalini, C | 1 |
| Perucca, E | 1 |
| Gelisse, P | 1 |
| Genton, P | 1 |
| Raybaud, C | 1 |
| Thiry, A | 1 |
| Pincemaille, O | 1 |
| Alla, P | 1 |
| Philip, N | 1 |
| Azulay, JP | 1 |
| Attarian, S | 1 |
| Pouget, J | 1 |
| Straussberg, R | 1 |
| Kivity, S | 1 |
| Weitz, R | 1 |
| Harel, L | 1 |
| Gadoth, N | 1 |
| Chen, G | 1 |
| Sveberg Røste, L | 1 |
| Taubøll, E | 1 |
| Berner, A | 1 |
| Berg, KA | 1 |
| Aleksandersen, M | 1 |
| Gjerstad, L | 1 |
| Vainstein, G | 1 |
| Korzets, Z | 1 |
| Pomeranz, A | 1 |
| Gadot, N | 1 |
| Yamamoto, K | 1 |
| Fukusako, T | 1 |
| Nogaki, H | 1 |
| Morimatsu, M | 1 |
| Verbiest, HB | 1 |
| Straver, JS | 1 |
| Colombo, JP | 1 |
| van der Vijver, JC | 1 |
| van Woerkom, TC | 1 |
| Walker, RM | 1 |
| Smith, GS | 1 |
| Barsoum, NJ | 1 |
| Macallum, GE | 1 |
| Takeno, Y | 1 |
| McLachlan, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)[NCT00071721] | Phase 3 | 313 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver rating questionnaire for the assessment of agitation in older persons. It includes descriptions of 29 agitated behaviors, each rated on a 7-point scale of frequency. The range of this instrument is 29 to 203 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 10.6 |
| Placebo | 12.1 |
Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year (ADAS-cog) is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 42.3 |
| Placebo | 41.9 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Score (ADCS-ADL) is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 35.1 |
| Placebo | 41.0 |
Clinical Dementia Rating, Sum of Boxes (CDR-SOB) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 12.0 |
| Placebo | 11.5 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) provides a means to reliably assess global change from baseline. It provides a semi-structured format to allow clinicians to gather necessary clinical information from both the participant and informant, in order to make an overall impression of clinical change. The range of this instrument is 1 to 7 with lower numbers indicating improvement and higher numbers indicating a worsened state. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 5.7 |
| Placebo | 5.5 |
NPI quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, and others. This is a questionnaire administered to the subject's study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment. To determine whether or not psychosis or agitation is present, there is no cutoff score but is based on the clinician's judgment. In the NPI, the subject responds to 'Yes' or 'No' questions. Then it is determined how often psychosis or agitation occurs and if it is mild, moderate or severe. (NCT00071721)
Timeframe: 24 months
| Intervention | Participants (Number) |
|---|---|
| Valproate | 25 |
| Placebo | 29 |
1 review available for valproic acid and Atrophy
| Article | Year |
|---|---|
The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
Topics: Anticonvulsants; Apoptosis; Atrophy; Brain; Central Nervous System Diseases; Gene Expression; Genes, | 2003 |
2 trials available for valproic acid and Atrophy
| Article | Year |
|---|---|
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium use and brain atrophy in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Atrophy; Brain; Double-Blind Metho | 2011 |
34 other studies available for valproic acid and Atrophy
| Article | Year |
|---|---|
Occipital epilepsy versus progressive myoclonic epilepsy in a patient with continuous occipital spikes and photosensitivity in electroencephalogram: A case report.
Topics: Anticonvulsants; Atrophy; Cerebral Cortex; Diagnosis, Differential; Disease Progression; Electroence | 2018 |
The Notch signaling pathway inhibitor Dapt alleviates autism-like behavior, autophagy and dendritic spine density abnormalities in a valproic acid-induced animal model of autism.
Topics: Animals; Atrophy; Autistic Disorder; Autophagy; Beclin-1; Behavior, Animal; Cerebellum; Dendritic Sp | 2019 |
[Lennox-Gastaut syndrome: Experience of Marrakech University Hospital].
Topics: Accidental Falls; Anticonvulsants; Asphyxia Neonatorum; Atrophy; Cerebral Cortex; Child; Child, Pres | 2013 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
Hemiconvulsion-hemiplegia-epilepsy syndrome: clinical course and neuroradiological features in a 20-month-old girl.
Topics: Anticonvulsants; Atrophy; Brain; Carbamazepine; Epilepsy; Female; Hemiplegia; Humans; Infant; Syndro | 2014 |
Valproate-induced pseudoatrophy: expanding the clinical and imaging spectrum.
Topics: Anticonvulsants; Atrophy; Brain; Child; Cognition Disorders; Humans; Magnetic Resonance Imaging; Mag | 2014 |
Valproate induced cerebellar atrophy presenting as movement disorder.
Topics: Adult; Anticonvulsants; Atrophy; Cerebellum; Electroencephalography; Epilepsy, Tonic-Clonic; Female; | 2017 |
Mechanism of valproic acid-induced Fanconi syndrome involves mitochondrial dysfunction and oxidative stress in rat kidney.
Topics: Adenosine Triphosphate; Animals; Atrophy; Disease Models, Animal; Fanconi Syndrome; Glutathione; Kid | 2018 |
Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient.
Topics: Atrophy; Bipolar Disorder; Brain; Female; Humans; Hyperammonemia; Middle Aged; Neurotoxicity Syndrom | 2009 |
Cerebellar atrophy in a child with valproate toxicity.
Topics: Anticonvulsants; Atrophy; Cerebellum; Child; Humans; Hyperammonemia; Male; Valproic Acid | 2011 |
Alexander disease with mild dorsal brainstem atrophy and infantile spasms.
Topics: Alexander Disease; Anticonvulsants; Atrophy; Brain Stem; Brain Waves; Corpus Callosum; DNA Mutationa | 2013 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
Reversible altered consciousness with brain atrophy caused by valproic acid.
Topics: Atrophy; Brain; Child, Preschool; Consciousness Disorders; Electroencephalography; Epilepsy; Female; | 2003 |
Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma.
Topics: Atrophy; Coma; Evoked Potentials; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Rett Syndro | 2005 |
Cingulate cortex anatomical abnormalities in children and adolescents with bipolar disorder.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Atrophy; Bipolar Disorder; Brain; Brain Mapping; Ch | 2005 |
Antimyoclonic effect of levetiracetam in MERRF syndrome.
Topics: Activities of Daily Living; Anticonvulsants; Atrophy; Brain; Drug Therapy, Combination; Female; Gene | 2006 |
Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation.
Topics: Adult; Aged; Anticonvulsants; Atrophy; Brain; Child; Cognition Disorders; Developmental Disabilities | 2006 |
Cytoskeleton of hippocampal neurons as a target for valproic acid in an experimental model of depression.
Topics: Animals; Antidepressive Agents; Atrophy; Behavior, Animal; Cytoskeleton; Depression; Hippocampus; Im | 2007 |
A case of catatonia resembling frontotemporal dementia and resolved with electroconvulsive therapy.
Topics: Anti-Arrhythmia Agents; Anticonvulsants; Antimanic Agents; Atrophy; Atropine; Bipolar Disorder; Cata | 2009 |
Reversible dementia and apparent brain atrophy during valproate therapy.
Topics: Atrophy; Brain Diseases; Child; Child, Preschool; Dementia; Epilepsy; Female; Humans; Magnetic Reson | 1995 |
Valproic acid-induced hyperammonemic encephalopathy: MR appearance.
Topics: Adult; Ammonia; Atrophy; Brain Diseases, Metabolic; Cerebral Cortex; Diagnosis, Differential; Epilep | 1994 |
[West's syndrome in patients with cerebral paralysis and periventricular leukomalacia: a good response to treatment].
Topics: Anticonvulsants; Atrophy; Cerebral Palsy; Cerebral Ventricles; Child; Child, Preschool; Female; gamm | 1997 |
Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment.
Topics: Atrophy; Brain; Brain Diseases; Child; Cognition Disorders; Diagnosis, Differential; Electroencephal | 1998 |
Benign childhood epilepsy with centrotemporal spikes and hippocampal atrophy.
Topics: Atrophy; Cerebral Cortex; Child; Electroencephalography; Epilepsy, Rolandic; Hippocampus; Humans; Ma | 1999 |
[Epilepsy in an adult with chromosome 22q11 micro-deletion].
Topics: Adult; Anticonvulsants; Atrophy; Brain; Chromosome Deletion; Chromosomes, Human, Pair 22; DiGeorge S | 1999 |
Reversible cortical atrophy and cognitive decline induced by valproic acid.
Topics: Adolescent; Anticonvulsants; Atrophy; Cerebral Cortex; Cognition Disorders; Electroencephalography; | 1998 |
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness.
Topics: Affect; Antimanic Agents; Atrophy; Bipolar Disorder; Brain; Calcium-Calmodulin-Dependent Protein Kin | 2000 |
Morphological changes in the testis after long-term valproate treatment in male Wistar rats.
Topics: Animals; Anticonvulsants; Atrophy; Biomarkers, Tumor; Dose-Response Relationship, Drug; Flow Cytomet | 2001 |
Deepening coma in an epileptic patient: the missing link to the urea cycle. Hyperammonaemic metabolic encephalopathy.
Topics: Anticonvulsants; Atrophy; Cerebellum; Coma; Epilepsy; Female; Humans; Hyperammonemia; Middle Aged; T | 2002 |
[Multiple system atrophy with macro square wave jerks and pendular nystagmus].
Topics: Atrophy; Baclofen; Brain Diseases; Diazepam; Electrooculography; Eye Movements; Female; Humans; Midd | 1992 |
Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.
Topics: Adult; Amino Acid Metabolism, Inborn Errors; Ammonia; Atrophy; Carbamoyl-Phosphate Synthase (Ammonia | 1992 |
Preclinical toxicology of the anticonvulsant calcium valproate.
Topics: Animals; Anticonvulsants; Atrophy; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclini | 1990 |
[Evaluation of bone atrophy by microdensitometry and effect of active vitamin D3 (1 alpha-OH-D3) administration in patients receiving anticonvulsants].
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Anticonvulsants; Atrophy; Bone and Bones; Bone Dens | 1989 |
Pseudoatrophy of the brain with valproic acid monotherapy.
Topics: Adolescent; Atrophy; Brain; Cerebral Ventricles; Cognition Disorders; Electroencephalography; Epilep | 1987 |